Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
RESEARCH TOOLSreports
Entrada Therapeutics Inc (TRDA) Stock Price & Analysis
54 Followers
TRDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.62 - $18.44
Previous Close$14.49
Volume89.05K
Average Volume (3M)78.86K
Market Cap
$489.17M
Enterprise Value$489.80M
Total Cash (Recent Filing)$67.60M
Total Debt (Recent Filing)$68.23M
Price to Earnings (P/E)23.1
Beta0.44
Next Earnings
Aug 07, 2024EPS Estimate
$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.63
Shares Outstanding33,758,976
10 Day Avg. Volume59,201
30 Day Avg. Volume78,860
Standard Deviation0.26
R-Squared0.00634
Alpha0.00914
Financial Highlights & Ratios
Price to Book (P/B)1.98
Price to Sales (P/S)3.79
Price to Cash Flow (P/CF)-29.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.80
Enterprise Value/Gross Profit3.80
Enterprise Value/Ebitda-40.40
Forecast
1Y Price Target
$20.00Price Target Upside33.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Entrada Therapeutics Inc News
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressClinical trials for the myotonic dystrophy type 1 treatment are advancing, with Phase 1/2 trial enrollment already underway.
Innovation And R&DEntrada Therapeutics is developing its Endosomal Escape Vehicle platform, which has the potential to access new intracellular targets previously considered inaccessible.
Strategic PartnershipsThe research and license agreement with Vertex for VX-670 shows a strategic partnership that could enhance Entrada's financial and developmental capabilities.
Bears Say
Drug Development DelaysENTR-601-44 remains on clinical hold in the U.S. following communication from the FDA.
EarningsFull-year 2023 financial results reported a net loss greater than anticipated, with a revised full-year 2024 net loss estimate due to higher operating expenses.
Regulatory ChallengesThe FDA issued a clinical hold on the IND submission for Entrada's lead candidate, ENTR-601-44, and the nature of the hold hasn't been disclosed.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $10.62 and its highest was $18.44 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Currently, no data Available
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is Aug 07, 2024 which is in 83 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on May 09, 2024. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of -$0.594 by $1.274.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is $0.12.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 33,758,976 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of $0.68 in its last earnings report, beating expectations of -$0.594. Following the earnings report the stock price went up 2.206%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Among the largest hedge funds holding Entrada Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Entrada Therapeutics Inc’s shares valued at 69M.
---
Entrada Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (33.78% Upside)
$20.00 (33.78% Upside)
Insider Transactions
Bought Shares
Worth $660.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.20%
12-Months-Change
Fundamentals
Return on Equity
9.41%
Trailing 12-Months
Asset Growth
7.42%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
---
TRDA Stock 12 Month Forecast
Average Price Target
$20.00
▲(33.78% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Best Analysts Covering TRDA
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+6.08%
reiterated a buy rating 9 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +6.08% per trade.
---